Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis

Published:2020-05 Issue:10235 Volume:395 Page:1487-1495
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Chiarito Mauro,Sanz-Sánchez Jorge,Cannata Francesco,Cao Davide,Sturla Matteo,Panico Cristina,Godino Cosmo,Regazzoli Damiano,Reimers Bernhard,De Caterina Raffaele,Condorelli Gianluigi,Ferrante Giuseppe,Stefanini Giulio G

Publisher

Elsevier BV

Subject

General Medicine

Reference41 articles.

1. Decline in cardiovascular mortality: possible causes and implications;Mensah;Circ Res,2017

2. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association;Kernan;Stroke,2014

3. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes;Knuuti;Eur Heart J,2020

4. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)

5. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS

Cited by 123 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Antithrombotic Therapy in Patients with Chronic Coronary Syndromes;Interventional Cardiology Clinics;2024-10

2. 2024 ESC Guidelines for the management of chronic coronary syndromes;European Heart Journal;2024-08-30

3. What US Cardiology Can Learn From the 2023 ESC Guidelines for the Management of Acute Coronary Syndromes;Clinical Cardiology;2024-08

4. P2Y12 Inhibitor Monotherapy After Short-Term Dual Antiplatelet Therapy in Acute Coronary Syndrome;The American Journal of Cardiology;2024-08

5. P2Y12 Receptor Inhibitor for Antiaggregant Therapies: From Molecular Pathway to Clinical Application;International Journal of Molecular Sciences;2024-07-10